Combining 2-deoxy-D-glucose with electron transport chain blockers: a double-edged sword.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents.International journal of molecular sciences · 2019
   Review
2. Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death.The Biochemical journal · 2016
   Article
3. Energy disruptors: rising stars in anticancer therapy?Oncogenesis · 2016
   Review
4. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.Molecular cancer research : MCR · 2014
   Article
5. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo.Clinical & experimental metastasis · 2011
   Article

Corrections and comments

• Comment on
  Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells.2009

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as